Dachille Douglas A. 4

4 · BridgeBio Pharma, Inc. · Filed Jun 24, 2026

AI-generated summary of this filing

Updated Jun 24, 2026

BridgeBio (BBIO) Director Douglas Dachille Receives RSU Award

What Happened

Douglas A. Dachille, a director of BridgeBio Pharma, received equity awards on 2026-06-22: 3,990 restricted stock units (RSUs) and 5,277 RSUs recorded as a derivative grant. Both awards were granted at $0.00 per unit (no cash paid). Total units granted = 9,267 RSUs; current reported value at grant = $0.

Key Details

Transaction date: 2026-06-22; Form 4 filed 2026-06-24 (timely).
Grants: 3,990 RSUs (non-derivative) and 5,277 RSUs (derivative) at $0.00.
Vesting: RSUs vest in full on 2027-06-22, subject to continued service on the board.
Derivative explanation: Each RSU represents a contingent right to receive one share of common stock upon vesting.
Ownership note: The 5,277 units are owned directly by The Dachille 2012-1 Family Trust for the benefit of the reporting person’s children; the reporting person disclaims beneficial ownership of those trust-held securities.
Shares owned after transaction: Not specified in the filing.
Other: Exhibit 24 (Power of Attorney) attached to the filing.

Context

These are time-based RSU grants (award), not purchases or sales — they do not require cash from the director and do not signal an immediate market action. The awards simply give the right to receive shares if the director remains in service through the 2027 vest date.

Form 4

Period: 2026-06-22

Director

Transactions

Award
Common Stock
[F1][F2]
2026-06-22+3,990→ 10,579 total
Award
Stock Option (Right to Buy)
[F4]
2026-06-22+5,277→ 5,277 total
Exercise: $68.92Exp: 2036-06-21→ Common Stock (5,277 underlying)

Holdings

Footnotes (4)

[F1]Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
[F2]Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
[F3]These shares are owned directly by The Dachille 2012-1 Family Trust for the benefit of the Reporting Person's children, for which the Reporting Person's spouse is the trustee. The Reporting Person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for Section 16 or any other purpose.
[F4]The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

Signature

/s/ Will Solis, Attorney-in-Fact|2026-06-24

4 files